

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF TECHNOLOGY OFFICER

The Board (the “**Board**”) of directors (the “**Director(s)**”) of Innovative Pharmaceutical Biotech Limited (“**Company**”) is pleased to announce that Dr. Li Peilun (“**Dr. Li**”) will be appointed as the chief technology officer of the Company with effect from 29 July 2025.

Dr. Li Peilun (李沛倫), aged 31, earned his bachelor’s degree from the Yao Class at Tsinghua University and his doctorate from the Institute for Interdisciplinary Information Sciences at Tsinghua University. After graduation, he joined the Tree-Graph Blockchain Research Institute, where he currently serves as a technical expert. His research focuses on blockchain and distributed systems.

As project leader, he was responsible for the 2023 sub-project under China’s national “Blockchain” key initiative, titled “R&D of Fundamental Technologies and Systems for Ultra-Large-Scale Blockchain Infrastructure.” He has published multiple papers at certain international computer systems conferences such as OSDI, ATC, and SoCC. His research contributions in blockchain have been cited over 500 times, and he holds more than ten invention patents, including three U.S. patents that have been officially granted.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 29 July 2025

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).